Clinical trials: Pelvic Cancer
Lymphoceles Following Pelvic Lymph Node Dissection
Cold Plasma for the Reduction of Lymphoceles Following PLND
This study protocol will evaluate the efficacy of Bovie Medical's J-Plasma® helium based plasma technology in the reduction of lymphoceles following pelvic lymph node dissection (PLND) during robotic assisted radical…
- Trial name
- NCT02658851
- Testing
- J-Plasma
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Apyx Medical
Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or…
- Trial name
- NILE (NCT03682068)
- Testing
- Durvalumab, Tremelimumab, Cisplatin + Gemcitabine
- Where
- 222 sites in United States, Argentina and 20 more
- Volunteers
- 1,246 people
- Sponsor
- AstraZeneca
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
This study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI) that is used to treat patients with cancer of the…
- Conditions
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms
- Trial name
- EV-103 (NCT03288545)
- Testing
- enfortumab vedotin (EV), pembrolizumab, cisplatin
- Where
- 106 sites in United States, Canada and 4 more
- Volunteers
- 348 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Genital Neoplasms, Female, Fallopian Tube Neoplasms
A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.
This trial compares two chemotherapy agents for the treatment of recurrent ovarian, fallopian or primary peritoneal cancer in patients that have received and are no longer responding to Platinum based treatment.
- Conditions
- Genital Neoplasms, Female, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pelvic Neoplasms
- Trial name
- NCT00191607
- Testing
- Gemcitabine, liposomal doxorubicin
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- Eli Lilly and Company
Head and Neck Cancer, Breast Cancer
Evaluation of Improved Onboard Patient Imaging
The primary objective of radiation therapy is to deliver a therapeutic dose of radiation precisely to the target while minimizing exposure to healthy surrounding tissues.
- Conditions
- Head and Neck Cancer, Breast Cancer, Upper Gastrointestinal Cancer, Lung Cancer
- Trial name
- NCT06187103
- Testing
- HyperSight Imaging
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Varian, a Siemens Healthineers Company
Adnexal Mass, Ovarian Cancer
Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy
Venn Biosciences Corporation ("InterVenn") has developed a liquid biopsy that is capable of distinguishing benign from malignant masses in women presenting with adnexal (pelvic) masses, through a simple blood test.
- Conditions
- Adnexal Mass, Ovarian Cancer, Pelvic Mass
- Trial name
- VOCAL (NCT03837327)
- Where
- 26 sites in United States, Australia and 2 more
- Volunteers
- 1,025 people
- Sponsor
- Venn Biosciences Corporation
Ovarian Tumor
Assess Cancer in Ovarian Tumors With Biomarkers.
Purpose The OvaRI assay clinical trial is directed at evaluating a novel proteomics-based blood test. This test is for a physician to use towards differentiating benign from malignant ovarian tumors prior to surgical…
- Trial name
- NCT00436189
- Testing
- Blood Draw
- Where
- 18 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Ciphergen Biosystems
Ovarian Neoplasms
Evaluation of Multiple Biomarkers to Estimate Risk of Ovarian Cancer in Patients With a Pelvic Mass.
ANGLE has developed the Parsortix™ Cell Separation System (Parsortix), an automated system capable of harvesting rare circulating cells for analysis from a sample of peripheral blood based on cellular size and deformability.
- Trial name
- NCT02785731
- Testing
- Pelvic imaging, Blood draw, laparotomy or laparoscopy
- Where
- 5 sites in Austria, Germany
- Volunteers
- 204 people
- Sponsor
- Angle plc
Liver Metastasis, Pelvic Cancer
Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors
This multi-center photodynamic therapy study plans to treat patients with large tumors in any superficial location, sarcoma, tumors of oral/oro-pharyngeal cavity, tumors with extensive pelvic involvement, or liver metastasis.
- Conditions
- Liver Metastasis, Pelvic Cancer, Head and Neck Cancer, Sarcoma
- Trial name
- NCT00028405
- Testing
- LS 11(Taporfin Sodium), Lumaflex Light Delivery Catheter
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Light Sciences LLC
Prostate Cancer
Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])
This is an open-label, nonrandomized, multicenter study conducted in two sequential parts: an initial Phase 2 Dose Optimization Period followed by the Phase 3 Diagnostic Performance Period.
- Trial name
- SPARROW (NCT07831824)
- Testing
- [68Ga]-LNTH-2401
- Where
- United States
- Volunteers
- 408 people
- Sponsor
- Lantheus Medical Imaging
Thoracic Cancer, Head and Neck Cancer
SCINTIX [BgRT} Using RMRS in Solid and Soft Tissue Tumors
This study proposes 6 anatomic groupings which each can be defined similarly as the "head and neck" grouping above. These 6 groupings are: (1) Head and Neck, (2) Thoracic not including lung parenchymal, (3) Hepatobiliary and…
- Conditions
- Thoracic Cancer, Head and Neck Cancer, Pelvic Cancer, Hepatobiliary Carcinoma in Situ
- Trial name
- NCT06634706
- Testing
- RefleXion X1 Radiotherapy System [Imaging Only]
- Volunteers
- 96 people
- Sponsor
- RefleXion Medical
Radiotherapy Side Effect, Pelvic Cancer
AI as an Aid for Weekly Symptom Intake in Radiotherapy
The study investigates the use of artificial intelligence (AI) and large language models (LLMs) to enhance the efficiency and accuracy of weekly treatment consultations (OTVs) in radiotherapy.
- Conditions
- Radiotherapy Side Effect, Pelvic Cancer, Patient
- Trial name
- NCT06525181
- Testing
- Generative Artificial Intelligence, Standard weekly symptom intake
- Where
- Brazil
- Volunteers
- 200 people
- Sponsor
- jaide
Prostate Cancer, Prostate Adenocarcinoma
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.
- Trial name
- Solar-Stage (NCT06235151)
- Testing
- Copper Cu 64 PSMA I&T
- Where
- 43 sites in United States
- Volunteers
- 439 people
- Sponsor
- Curium US LLC
Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter
Named Patient Program for Mitomycin for Pyelocalyceal Solution
This program provides controlled, pre-approval access to JELMYTO in response to unsolicited requests by physicians, hospitals, pharmacies, distributors, ministries of health or other parties on behalf of specific, or named…
- Conditions
- Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent
- Trial name
- NCT05494411
- Testing
- Mitomycin for pyelocalyceal solution
- Sponsor
- UroGen Pharma Ltd.
Bone Tumor, Osteoporosis
U.S. Prospective Evaluation of EPIONE Device for Percutaneous MSK Procedures
The goal of this investigational device exemption is to evaluate the Epione assistance for introducer placement during percutaneous procedures in musculo-skeletic (MSK) structures of the pelvis and the spine in adults.
- Conditions
- Bone Tumor, Osteoporosis, Traumatic Fracture
- Trial name
- EPIOS (NCT07325578)
- Testing
- Percutaneous procedure in the MSK structures of the pelvis and/or the spine
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Precision IO Group
Uterine Fibroids, Bleeding
Study to Evaluate the Safety and Effectiveness of MRgFUS Compared With Myomectomy for the Treatment of Uterine Fibroids
The objective of this trial is to evaluate the safety and efficacy of ExAblate for the treatment of uterine fibroids. Women, seeking treatment for symptomatic uterine leiomyomata will be eligible for the study.Women who agree to…
- Conditions
- Uterine Fibroids, Bleeding, Pelvic Pain
- Trial name
- NCT01328067
- Testing
- Exablate 2100, Myomectomy
- Where
- United Kingdom
- Sponsor
- InSightec
Prostate Cancer
A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology
This was a multicenter, multi-reader, open-label, Phase 2 study assessing the safety and performance characteristics of MIP 1404 imaging in the detection of prostate gland and pelvic lymph node cancer.
- Trial name
- NCT01667536
- Testing
- Drug: 99mTc-MIP-1404
- Where
- 35 sites in United States, Belgium and 6 more
- Volunteers
- 105 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Prostate Cancer
Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC
The purpose of this trial is to learn more about the effects of AAA602 and AAA802 in men with prostate-specific membrane antigen (PSMA) positive high-risk localized prostate cancer (HRLPC) before surgery to remove the prostate…
- Trial name
- NeoPSMA (NCT06881823)
- Testing
- AAA602, AAA802, Gallium (68Ga) gozetotide
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
This is a study that will test how an experimental drug (enfortumab vedotin) affects patients with cancer of the urinary system (urothelial cancer).
- Conditions
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms
- Trial name
- EV-201 (NCT03219333)
- Testing
- Enfortumab vedotin
- Where
- 81 sites in United States, France and 6 more
- Volunteers
- 219 people
- Sponsor
- Astellas Pharma Inc
Breast Cancer, Lung Cancer
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens to evaluate biomarkers associated with cancer for diagnostic assay development.
- Conditions
- Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT03662204
- Testing
- Blood Sample Collection
- Where
- 119 sites in United States
- Volunteers
- 5,133 people
- Sponsor
- Exact Sciences Corporation